SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline efficacy results from its Phase 1 / 2 ...
SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1 clinical trial of DARE-HRT1.
Hosted on MSN
Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy
Johnson reiterated the targeted Q4 2025 launch for DARE to PLAY Sildenafil cream through a 503B outsourcing facility. She stated, "We remain on track to support a fourth quarter 2025 launch." ...
Based on the estradiol PK data in the DARE-HRT1 Phase 1 / 2 study, the results support the potential of DARE-HRT1 as an effective hormone therapy for both VMS and vaginal symptoms associated with ...
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced positive topline results from its Phase 1 clinical trial of ...
Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and ...
The First Clinical Study Using the Novel Segmented Intravaginal Ring (IVR) Technology Validates its Potential to Provide a Versatile Convenient Drug Delivery Solution SAN DIEGO, June 28, 2021 (GLOBE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results